Management Tips for Obesity, Metabolic Health, and Diabetes

Learn how obesity affects diabetes and metabolic health. This post delves into important health connections for you.

Abstract

Metabolic health is a cornerstone of overall well-being. In this comprehensive educational post, I will explain how obesity functions as a chronic, progressive, relapsing—but treatable—disease that drives prediabetes, dyslipidemia, hypertension, type 2 diabetes, and cardiovascular disease. These conditions are interconnected through shared physiological mechanisms like chronic inflammation, endocrine dysregulation, and mitochondrial dysfunction. I will walk you through a detailed journey, including representative case studies, to show how a multifaceted, integrative approach can lead to significant, sustainable health improvements. You will learn the physiological rationale behind modern treatments, the powerful insights from continuous glucose monitoring (CGM), the role of advanced pharmacotherapy such as GLP-1 receptor agonists, and how menopausal hormone therapy (MHT) can modulate metabolic health. Throughout, I will share insights from leading researchers and highlight how our multidisciplinary team at Injury Medical Clinic PA in El Paso, Texas, integrates internal medicine, functional medicine, rehabilitation, and integrative chiropractic care to create synergistic, evidence-based treatment plans that can help patients reclaim their health and prevent the progression to chronic disease.

Our Collaborative Care Model at Injury Medical Clinic

At Injury Medical Clinic PA, also known as Mission Plaza Injury Medical Clinic, our philosophy is rooted in integrative and multidisciplinary care. My practice is built on the principle that true healing requires a holistic approach. I am Dr. Alex Jimenez, and I hold credentials as a Doctor of Chiropractic (DC), an Advanced Practice Registered Nurse (APRN), and a board-certified Family Nurse Practitioner (FNP-BC), along with advanced certifications in functional and lifestyle medicine.

This unique combination of expertise allows us to view patient health through multiple lenses. We provide comprehensive care under the expert medical direction of Dr. Maria Guadalupe Cardenas, MD. Dr. Cardenas is Board Certified in Internal Medicine and brings over 40 years of invaluable experience to our team. As our Medical Director and Collaborative Physician (NPI #1164426749, Texas MD License #J2933), she provides essential medical oversight, ensuring our treatment plans are safe, effective, and grounded in the best practices of modern medicine. This multidisciplinary structure, in which an MD provides medical direction alongside a chiropractor, is common and reflects the modern, collaborative standard in integrative and injury-care clinics.

Together, our team integrates:

• Medical Oversight (Internal Medicine): Cardenas confirms complex diagnoses, coordinates labs, imaging, and pharmacotherapy, and directs cardiometabolic risk management with guideline-concordant care. She also coordinates with specialists like cardiologists, hepatologists, and endocrinologists.
• Integrative Chiropractic Care: I apply evidence-based spinal and extremity adjustments, myofascial therapies, and neurologic mobility drills to reduce pain, improve autonomic balance, and enhance movement efficiency, all of which are foundational for physical activity.
• Functional Medicine: We delve deep to identify and address the root causes of dysfunction, from metabolic imbalances and nutritional deficiencies to hormonal dysregulation and environmental exposures.
• Personal Injury and Rehabilitation: We provide specialized care to restore function and mobility after an injury. This is critical, as injury can derail activity and weight management, and post-traumatic stress elevates cardiometabolic risk.
• Nutrition and Lifestyle Counseling: We empower patients with the knowledge and tools to achieve sustainable change, often using technology such as CGM for real-time feedback.

This collaborative model is particularly powerful when addressing complex conditions like obesity and diabetes, where a single approach is rarely sufficient. By combining our strengths, we create a personalized and robust treatment strategy for each patient.

Why Obesity Is the Root Driver: The Physiological Story

Obesity is not simply a matter of eating more and moving less. It is a tightly regulated biological process in which hormones of hunger and satiety (e.g., ghrelin, leptin, GLP-1, PYY) become dysregulated. I often explain this to my patients as: overeating does not cause obesity—obesity causes overeating once the homeostatic system is disrupted. Early in the disease process, hypothalamic inflammation impairs neuronal signaling in key brain regions that control appetite (like the arcuate nucleus and paraventricular nucleus). This blunts satiety signals and enhances the brain’s reward-driven (hedonic) drive to eat. Over time, as fat mass increases, the brain begins to defend this higher weight by lowering energy expenditure, increasing hunger, and causing persistent weight regain after dieting—a phenomenon known as metabolic adaptation.

• Key physiological mechanisms:

• • Endocrine dysregulation: Elevated ghrelin (the “hunger hormone”), reduced sensitivity to leptin (the “satiety hormone”), and altered insulin and incretin signaling drive increased food intake and reduced energy expenditure (Rosenbaum & Leibel, 2010; Sumithran et al., 2011).
  • Inflammation and neurobiology: Microglial activation and inflammatory cytokine signaling (e.g., TNF-α, IL-6) in the hypothalamus contribute directly to leptin resistance and dysregulated appetite control (Thaler et al., 2012).
  • Mitochondrial dysfunction and lipotoxicity: When fat cells are overwhelmed, lipids are stored ectopically (in the wrong places), such as the liver, muscle, and heart. This “lipotoxicity” increases oxidative stress and causes insulin resistance (Samuel & Shulman, 2016).
  • Nitric oxide (NO) impairment: Chronic inflammation reduces the bioavailability of endothelial nitric oxide, a critical molecule for vascular health. This promotes vasoconstriction, platelet aggregation, and endothelial dysfunction. NO also supports glucose disposal and mitochondrial efficiency; its reduction links obesity to both metabolic and cardiovascular disease (Sansbury & Hill, 2014).

The Challenge of Prediabetes and Obesity: A Clinical Case Study

To illustrate our approach, let’s explore a case representative of many individuals I see in my practice. “Stephen,” a 24-year-old man, came to my clinic for a follow-up on prediabetes and weight management.

• Initial Diagnosis: Six months prior, he was diagnosed with prediabetes, marked by a hemoglobin A1c of 5.8%.
• Patient History: Stephen’s weight gain began at age 13, coinciding with the stress of his parents’ divorce. This highlights a crucial point: stress and emotional health are deeply intertwined with metabolic function. The stress hormone cortisol can promote visceral fat storage and influence food cravings.
• Family History: Both parents have obesity, cardiovascular disease, and type 2 diabetes, placing him at high genetic risk.
• Lifestyle: His work is sedentary, a major contributor to metabolic slowdown.
• Clinical Findings: At his visit, his weight was 250 pounds, his highest recorded weight. With a Body Mass Index (BMI) of 32.1, he was classified as having Class 1 Obesity.

A thorough assessment is the first and most critical step. My physical exam revealed several key metabolic markers:

• Waist Circumference: At 41 inches, his waist indicated high visceral adiposity—fat stored deep within the abdomen. This type of fat is highly inflammatory and a major risk factor for diabetes and heart disease.
• Neck Circumference: At 17 inches, his neck circumference is a risk factor for obstructive sleep apnea (OSA). Poor sleep further disrupts metabolic hormones, creating a vicious cycle of weight gain.
• Acanthosis Nigricans: I observed dark, velvety patches of skin on his neckline. This is a classic cutaneous sign of insulin resistance, in which the body’s cells do not respond effectively to insulin.

When I asked Stephen if he would be interested in a treatment that could not only help him lose weight but also prevent him from developing diabetes, his response was an enthusiastic “Absolutely yes!” This motivation is a key ingredient for success.

Setting Evidence-Based Goals: The Power of Weight Loss

Patients must understand why we are aiming for a specific amount of weight loss. It’s not about an arbitrary number; it’s about reversing the underlying pathophysiology.

• For Prediabetes: A modest 3% weight loss can improve glucose metabolism. However, a more substantial 10-15% weight loss is often needed to achieve remission of prediabetes and normalize blood sugar.
• For Other Complications: For conditions like type 2 diabetes, high cholesterol, hypertension, and metabolic dysfunction-associated steatotic liver disease (MASLD), a 15% or greater weight loss is associated with transformative improvements and potential disease remission.

This understanding helps frame our treatment decisions. Since intensive lifestyle interventions alone often yield only 5-8% weight loss, with weight regain common, we must consider more intensive therapies to achieve these transformative goals.

---

Chiropractic Care & Metabolism *The Hidden Link*- Video

---

Crafting a Multifaceted Treatment Plan for Stephen

Our plan for Stephen is based on evidence-based recommendations across nutrition, activity, behavior, and medical management, supported by our integrative care model.

Nutrition and Lifestyle Foundations

I explained to Stephen that there is no single “magic” diet. The most effective plan is sustainable and enjoyable. We focused on:

• Calorie Deficit: A moderate deficit of 500-750 calories per day.
• Macronutrient Quality: Emphasizing lean protein for satiety and muscle preservation, along with high-fiber vegetables, while reducing refined carbohydrates and sugary drinks.
• Expert Guidance: I recommended a referral to a Registered Dietitian for personalized medical nutrition therapy.

The Role of Integrative Chiropractic Care in Enhancing Physical Activity

Before starting any new exercise regimen, ensuring the body is mechanically sound is vital. This is where integrative chiropractic care plays a pivotal role.

• Biomechanical Assessment: As a chiropractor, I assess the patient’s spine, joints, and posture. A sedentary lifestyle often leads to musculoskeletal imbalances, such as forward head posture, rounded shoulders, and lower back pain, which can make exercise painful and discouraging.
• Spinal Adjustments and Mobilization: Gentle, evidence-informed adjustments can restore proper joint motion, alleviate nerve pressure, and reduce pain. For Stephen, this meant improving his spinal alignment to support activities like walking and resistance training without discomfort.
• Functional Rehabilitation: We don’t just adjust; we rehabilitate. I prescribed specific corrective exercises to strengthen weak core muscles, improve flexibility, and correct postural distortions. This prepares the body to handle increased physical demands safely and effectively.

By addressing these foundational issues, chiropractic care removes physical barriers to exercise, making activity recommendations more achievable. We set an initial goal for Stephen: increase his steps to 3,000 per day.

Advanced Medical Management: The Game-Changer

For patients like Stephen, with significant metabolic risk, lifestyle changes combined with modern medical therapy offer the best chance for success. After discussing all options, Stephen elected to start Tirzepatide.

Tirzepatide is a dual-agonist medication that acts on two receptors: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). This dual action has a powerful effect on metabolism:

• It enhances insulin secretion in response to food.
• It slows gastric emptying, which increases feelings of fullness.
• It acts on the brain to reduce appetite and food cravings.

The evidence is compelling. The SURMOUNT-1 trial showed that participants receiving tirzepatide achieved remarkable weight loss, with an average reduction of nearly 23% (Jastreboff et al., 2022). This is the level of weight loss needed for significant disease remission.

The Journey of Follow-Up and Progress

Treating chronic disease is a journey requiring continuous support.

• One-Year Follow-Up: The results were outstanding. Stephen had lost 50 pounds (a 20% loss of total body weight), bringing his BMI from 32.1 to 25.7. His A1c was now 4%—completely normal—and his lipid panel had normalized.

This success story is a powerful testament to a comprehensive, integrative approach. By treating obesity early and aggressively, we prevented the onset of type 2 diabetes.

Case Journeys Victoria and Benny

To further illustrate our integrative approach, let’s explore two more complex cases.

Case 1: Victoria Prediabetes, Menopause, and Obesity

Victoria, a 52-year-old Black woman, presented with weight gain (+15 lbs), prediabetes transitioning to diabetes (A1C 7.3%), and menopausal symptoms like night sweats and poor sleep. Her BMI was 31.8.

The Physiology of Menopause: The decline in estrogen reduces insulin sensitivity, increases visceral fat, and raises cardiovascular risk (El Khoudary et al., 2020). Sleep fragmentation from hot flashes further amplifies sympathetic drive and worsens appetite regulation (Thurston et al., 2023).

Our Integrated Plan:

1. CGM and Nutrition: We used a continuous glucose monitor (CGM) to provide real-time feedback. It showed pronounced post-dinner glucose spikes, revealing the impact of carbohydrate density and stress-related snacking.
2. Menopause Care: Under Dr. Cardenas’s direction, she was referred for menopause hormone therapy (MHT) consideration. Appropriately timed MHT can improve vasomotor symptoms and favorably influence lipids and insulin sensitivity (NAMS, 2023).
3. Step-Up Therapy: When lifestyle changes and metformin weren’t enough, we added a GLP-1 receptor agonist (semaglutide). This class of medication supports weight loss, improves A1C, and has proven cardiovascular benefits (Marso et al., 2016).
4. Integrative Chiropractic: I provided gentle spinal manipulation and myofascial release to improve her sleep quality and reduce sympathetic arousal. We also implemented progressive strength programming to build lean mass and enhance insulin sensitivity.

One Year Later: Victoria lost 25 pounds, her A1C and lipids improved, and her menopausal symptoms were controlled. The combination of MHT, GLP-1 therapy, and chiropractic support addressed her metabolic and hormonal challenges from multiple angles.

Case 2: Benny: Cardiovascular Disease, Diabetes, and Obesity

Benny, 64, presented with long-standing type 2 diabetes, a prior heart attack, hypertension, and a BMI of 36. His diet consisted of high-carbohydrate patterns, and he experienced frequent hunger, a classic sign of impaired satiety signaling.

Our Integrated Plan:

1. Cardiovascular Priority: For a patient with established cardiovascular disease, ADA guidelines recommend agents with proven cardiovascular benefit. We started semaglutide for its ability to reduce the risk of major adverse cardiovascular events and promote weight loss (ADA, 2024).
2. Liver Risk Screening: We calculated a FIB-4 score to screen for metabolic dysfunction-associated steatotic liver disease (MASLD), which is common among people with diabetes. His high-risk score prompted a referral to GI for further evaluation.
3. Adjunct Therapy for Cravings: After a year, Benny’s weight loss slowed and cravings returned. We added low-dose topiramate, which can help modulate reward-driven eating.
4. Integrative Chiropractic: I focused on thoracic mobility work to improve his breathing mechanics and CPAP tolerance for his sleep apnea. Lumbopelvic stabilization exercises reduced his pain during walking, enabling consistent activity, which is key for maintaining lean mass and insulin sensitivity.

Clinical Observations from Practice

Consistent with research, my clinical experience shows that patients who receive structured chiropractic care alongside medical and functional medicine oversight exhibit:

• Faster pain reduction and improved gait mechanics, allowing earlier initiation of walking and resistance programs.
• Better adherence to activity prescriptions, lower perceived exertion, and sustained weight loss beyond 6–12 months.
• Improved sleep quality and reduced stress reactivity, aligning with reductions in blood pressure and A1C.

These observations, which I also share through my work at Sciatica.clinic, align with data showing that movement and pain reduction improve cardiometabolic outcomes. The practical reality is that patients must feel well enough to stay active.

Metabolic Adaptation and Long-Term Care

Metabolic adaptation explains why weight regain is common after successful weight loss. As weight drops:

• Total energy expenditure declines disproportionately (adaptive thermogenesis).
• Ghrelin rises, and satiety hormones fall, elevating hunger.
• The brain defends prior adiposity set points, favoring regain.

This is biology, not a failure of willpower. Long-term pharmacotherapy and structured follow-up are essential. In trials, stopping anti-obesity medications such as semaglutide leads to rapid weight regain and adverse shifts in blood pressure and A1C (Wilding et al., 2021). We counsel patients to view obesity treatment as chronic care.

Conclusion: An Integrated Path to Lasting Health

Obesity drives diabetes and cardiovascular disease through intersecting mechanisms of inflammation, endocrine disruption, and mitochondrial stress. Durable outcomes require a comprehensive, long-term strategy: guideline-aligned medical care under an experienced internist; integrative chiropractic to reduce pain barriers and improve movement; functional medicine to address sleep, stress, and nutrition; and ongoing rehabilitation.

With coordinated care at Injury Medical Clinic PA, led by Dr. Cardenas and delivered by our multidisciplinary team, patients can achieve meaningful weight reduction, improved glycemic control, healthier blood pressure and lipid levels, and a better quality of life. Evidence-based, patient-centered management—anchored in physiology—allows us to turn short-term success into long-term health.

References

• American Diabetes Association. (2024). Standards of Care in Diabetes—2024. Diabetes Care, 47(Suppl 1).
• Apovian, C. M., Aronne, L. J., et al. (2022). Pharmacological management of obesity: An Endocrine Society clinical practice guideline. Journal of the Endocrine Society, 6(12), bvac059.
• Arnett, D. K., Blumenthal, R. S., et al. (2019). 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. Circulation, 140(11), e596–e646.
• Cani, P. D., et al. (2007). Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes, 56(7), 1761–1772.
• Colberg, S. R., et al. (2016). Physical Activity/Exercise and Diabetes: A Position Statement of the American Diabetes Association. Diabetes Care, 39(11), 2065–2079.
• El Khoudary, S. R., et al. (2020). Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association. Circulation, 142(20), e301–e320.
• Esposito, K., & Giugliano, D. (2006). The metabolic syndrome and inflammation: association or causation? Nutrition, Metabolism and Cardiovascular Diseases, 16(3), 163-165.
• Grundy, S. M., et al. (2019). 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Circulation, 139(25), e1082–e1143.
• Heindel, J. J., et al. (2015). Metabolism disrupting chemicals and obesity. Environmental Health Perspectives, 123(10), A260-A263.
• Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. The New England Journal of Medicine, 387(3), 205–216.
• Marso, S. P., et al. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. The New England Journal of Medicine, 375(19), 1834–1844.
• Rosenbaum, M., & Leibel, R. L. (2010). Adaptive thermogenesis in humans. Endocrine Reviews, 31(5), 643–664.
• Samuel, V. T., & Shulman, G. I. (2016). The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. Cell Metabolism, 23(3), 421- 435.
• Sansbury, B. E., & Hill, B. G. (2014). Regulation of obesity and insulin resistance by nitric oxide. American Journal of Physiology-Cell Physiology, 307(3), C235–C243.
• Sumithran, P., et al. (2011). Long-term persistence of hormonal adaptations to weight loss. The New England Journal of Medicine, 365(17), 1597–1604.
• Tasali, E., et al. (2008). Effect of sleep debt on metabolic and endocrine function in healthy men. Journal of Clinical Investigation, 118(3), 1013- 1019.
• Thaler, J. P., et al. (2012). Obesity is associated with hypothalamic injury in humans and mice. Journal of Clinical Investigation, 122(1), 153–162.
• The North American Menopause Society. (2023). The 2023 Hormone Therapy Position Statement of The North American Menopause Society. Menopause, 30(6), 599-617.
• Thurston, R. C., et al. (2023). Menopausal Vasomotor Symptoms and Risk of Incident Cardiovascular Disease Events in SWAN. Journal of the American College of Cardiology, 81(12), 1175-1185.
• Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine, 384(11), 989–1002.
• Wiviott, S. D., et al. (2019). Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. The New England Journal of Medicine, 380(4), 347–357.
• Zimmet, P., et al. (2016). The new world of diabetes: the pandemic and shifting demographics. Diabetologia, 59(7), 1381–1382.

SEO Tags: integrative chiropractic care, obesity treatment, cardiometabolic health, prediabetes, internal medicine collaboration, El Paso Injury Medical Clinic, hypothalamic inflammation, nitric oxide, GLP-1 semaglutide tirzepatide, SGLT2 inhibitors, metabolic adaptation, functional medicine, personal injury rehabilitation, diabetes cardiovascular overlap, weight loss guidelines, menopause hormone therapy, continuous glucose monitoring CGM, Dr. Maria Guadalupe Cardenas MD, Dr. Alex Jimenez DC, insulin resistance, SURMOUNT-1, lifestyle management, multidisciplinary care